Hsbc Holdings PLC purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 127,125 shares of the biotechnology company’s stock, valued at approximately $68,899,000.
Other institutional investors and hedge funds also recently modified their holdings of the company. Torren Management LLC bought a new stake in shares of United Therapeutics during the fourth quarter valued at about $26,000. Activest Wealth Management lifted its holdings in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the period. Fiduciary Financial Advisors bought a new position in United Therapeutics in the 2nd quarter valued at about $30,000. WealthCollab LLC grew its position in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares in the last quarter. Finally, Rakuten Securities Inc. increased its stake in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares during the period. Institutional investors own 94.08% of the company’s stock.
United Therapeutics Trading Down 0.4%
Shares of United Therapeutics stock opened at $516.68 on Thursday. United Therapeutics Corporation has a 52 week low of $302.19 and a 52 week high of $609.35. The stock has a market cap of $22.16 billion, a PE ratio of 18.49, a price-to-earnings-growth ratio of 1.76 and a beta of 0.59. The company’s 50-day moving average price is $531.06 and its two-hundred day moving average price is $538.56.
Wall Street Analysts Forecast Growth
UTHR has been the topic of a number of recent analyst reports. Weiss Ratings upgraded shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, August 13th. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Royal Bank Of Canada lowered their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Finally, Morgan Stanley set a $515.00 target price on United Therapeutics in a research report on Thursday, August 6th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $646.00.
View Our Latest Research Report on United Therapeutics
Insider Activity at United Therapeutics
In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $523.14, for a total value of $4,342,062.00. Following the transaction, the executive vice president owned 45,172 shares in the company, valued at approximately $23,631,280.08. The trade was a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $511.97, for a total value of $4,863,715.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at $166,105,082.71. This represents a 2.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 424,075 shares of company stock valued at $227,683,710. Company insiders own 8.60% of the company’s stock.
United Therapeutics Company Profile
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Stories
- Five stocks we like better than United Therapeutics
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR – Free Report).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
